What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace
By Holly Campbell | September 12, 2017
This post has been updated as of 10/2/2017 A recent study published in JAMA Internal Medicine provides flawed and inaccurate estimates of the significant research and development (R&D) investments...
Read More
340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients
By Rebecca Davison | April 27, 2017
As we’ve noted before, incentives to profit under the 340B program are leading to an uneven playing field for providers and may be shifting care to more expensive and less convenient settings in...
Read More
340B Spotlight: Retail pharmacies continue to expand the 340B program
By Rebecca Davison | August 17, 2016
One area of needed reform in the 340B program is the use of contract pharmacy arrangements. A new analysis by Drug Channels found more than one-in-four retail, mail and specialty pharmacies in...
Read More
340B Spotlight: New report raises questions about eligibility metric for 340B hospitals
By Karyn Schwartz | August 11, 2016
A new report from the Government Accountability Office (GAO) on how hospitals qualify for certain uncompensated care payments raises questions about how a similar eligibility metric is used to...
Read More
340B Spotlight: A look at 340B eligibility and charity care
By Allyson Funk | May 17, 2016
Last week the Alliance for Integrity and Reform of 340B (AIR340B)—of which PhRMA is a member—released a new report looking at charity care provided by 340B hospitals. This expands on previous...
Read More
340B Spotlight: Despite access to discounts, many 340B hospitals fail to comply with ACA charity care requirements
By Rebecca Davison | April 28, 2016
Late last year, we highlighted a study published in in the New England Journal of Medicine that found many nonprofit hospitals were not complying with the charity care requirements laid out in the
Read More
New report confirms competitive market works; Net prices for medicines increased just 2.8 percent in 2015
By Holly Campbell | April 14, 2016
Despite misleading claims made about spending on new innovative treatments and cures, another report confirms how the competitive biopharmaceutical market works to control costs. Net prices for...
Read More
New research: Insurance plan structure can have discriminatory effect
By Karyn Schwartz | March 31, 2016
New research from the Harvard University Center for Health Law and Policy Innovation (CHLPI) is another piece of evidence showing how health insurance plan design may be trying to discourage...
Read More
Medicare Monday (100)
340B Spotlight (36)
Cost & Consequence (0)
